12 Month Price Forecast For ENOV
Distance to ENOV Price Forecasts
ENOV Price Momentum
🤔 Considering Enovis (ENOV)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 10:49 AM UTC
ENOV Analyst Ratings & Price Targets
Based on our analysis of 17 Wall Street analysts, ENOV has a consensus that is bullish. The median price target is $63.50, with forecasts ranging from $50.00 to $75.00. Currently, there are 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With ENOV currently trading at $44.00, the median price forecast suggests a 44.3% upside. The most optimistic forecast comes from Caitlin Cronin at Canaccord Genuity, projecting a 70.5% upside, while Robbie Marcus at JP Morgan provides the most conservative target, suggesting a 13.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENOV Analyst Consensus
ENOV Price Target Range
Latest ENOV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENOV.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 7, 2024 | Needham | Mike Matson | Buy | Reiterates | $65.00 |
Oct 3, 2024 | JMP Securities | David Turkaly | Market Outperform | Initiates | $62.00 |
Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $58.00 |
Aug 8, 2024 | JP Morgan | Robbie Marcus | Neutral | Maintains | $50.00 |
Aug 8, 2024 | Needham | Mike Matson | Buy | Maintains | $65.00 |
Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $62.00 |
Jun 13, 2024 | JP Morgan | Robbie Marcus | Neutral | Initiates | $53.00 |
May 3, 2024 | Needham | Mike Matson | Buy | Reiterates | $82.00 |
Apr 10, 2024 | Needham | Mike Matson | Buy | Reiterates | $82.00 |
Feb 23, 2024 | Wells Fargo | Vik Chopra | Overweight | Maintains | $79.00 |
Feb 23, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $75.00 |
Feb 23, 2024 | Needham | Mike Matson | Buy | Maintains | $82.00 |
Feb 13, 2024 | Stephens & Co. | George Sellers | Overweight | Initiates | $72.00 |
Jan 22, 2024 | UBS | Danielle Antalffy | Buy | Initiates | $75.00 |
Jan 8, 2024 | Needham | Mike Matson | Buy | Maintains | $73.00 |
Jan 3, 2024 | William Blair | Brandon Vazquez | Outperform | Initiates | $0.00 |
Dec 20, 2023 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $71.00 |
Dec 15, 2023 | Needham | Mike Matson | Buy | Maintains | $70.00 |
Nov 8, 2023 | Needham | Mike Matson | Buy | Maintains | $62.00 |
Oct 20, 2023 | Needham | Mike Matson | Buy | Reiterates | $70.00 |
Stocks Similar to Enovis Corporation
The following stocks are similar to Enovis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enovis Corporation (ENOV) Financial Data
Enovis Corporation has a market capitalization of $2.54B with a P/E ratio of -72.1x. The company generates $2.00B in trailing twelve-month revenue with a -6.0% profit margin.
Revenue growth is +21.0% quarter-over-quarter, while maintaining an operating margin of +1.2% and return on equity of -3.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Enovis Corporation (ENOV) Company Overview
About Enovis Corporation
Medical technology company developing innovative solutions.
Enovis Corporation generates revenue through the manufacture and distribution of medical devices for reconstructive surgery, rehabilitation, and pain management. It operates in two main segments: Prevention and Recovery, which offers a variety of orthopedic and recovery solutions, and Reconstructive, which focuses on surgical implants and productivity tools. The company sells its products through independent distributors and directly under its ESAB and DJO brands.
Founded in 1995 and headquartered in Wilmington, Delaware, Enovis Corporation was previously known as Colfax Corporation. The company serves a wide range of healthcare professionals including orthopedic specialists, surgeons, and physical therapists, positioning itself as a key player in the medical technology sector.
Company Information
Sector
Industrials
Industry
Specialty Industrial Machinery
Employees
6,550
CEO
Mr. Matthew L. Trerotola
Country
United States
IPO Year
2022
Website
www.enovis.comEnovis Corporation (ENOV) Latest News & Analysis
Enovis, Omnicell, and Phreesia are featured in an Industry Outlook article, indicating potential relevance for investors in the healthcare and technology sectors.
Highlighting Enovis, Omnicell, and Phreesia suggests positive industry sentiment, potentially signaling growth opportunities or increased investor interest in these companies.
Stocks in the Medical Info Systems industry, including Enovis, Omnicell, and Phreesia, are anticipated to benefit from advancements in GenAI technology.
Stocks in the Zacks Medical Info Systems industry are poised for growth, driven by advancements in GenAI, signaling potential profitability and innovation in healthcare technology investments.
Enovis announced that Davide Visentin will replace Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.
Leadership changes can impact a company's strategic direction and operational effectiveness, influencing investor confidence and stock performance.
Enovis Corporation (NYSE: ENOV) will present at the J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PST. Details will be available on their website.
Enovis Corporation's presentation at a major healthcare conference signals potential insights into its growth strategy and innovations, impacting investor sentiment and stock performance.
Maplebear Inc. (CART) will replace Enovis Corp. (ENOV) in the S&P MidCap 400, while Enovis will take Arch Resources' place in the S&P SmallCap 600, effective January 14, 2025.
Maplebear's addition to the S&P MidCap 400 may boost its stock price due to increased visibility, while Enovis' shift to the SmallCap 600 reflects changes in market capitalization that could affect investor sentiment.
Enovis Corporation: Reasonably Valued With Caveats
2 months agoEnovis Corporation reported strong Q3 results on November 6, prompting analysts to maintain Buy ratings with price targets of $62 to $75, boosted by a recent acquisition.
Enovis Corporation's strong Q3 results and analyst Buy ratings indicate positive sentiment and potential stock appreciation, supported by growth from acquisitions and favorable valuations.
Frequently Asked Questions About ENOV Stock
What is Enovis Corporation's (ENOV) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Enovis Corporation (ENOV) has a median price target of $63.50. The highest price target is $75.00 and the lowest is $50.00.
Is ENOV stock a good investment in 2025?
According to current analyst ratings, ENOV has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ENOV stock?
Wall Street analysts predict ENOV stock could reach $63.50 in the next 12 months. This represents a 44.3% increase from the current price of $44.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enovis Corporation's business model?
Enovis Corporation generates revenue through the manufacture and distribution of medical devices for reconstructive surgery, rehabilitation, and pain management. It operates in two main segments: Prevention and Recovery, which offers a variety of orthopedic and recovery solutions, and Reconstructive, which focuses on surgical implants and productivity tools. The company sells its products through independent distributors and directly under its ESAB and DJO brands.
What is the highest forecasted price for ENOV Enovis Corporation?
The highest price target for ENOV is $75.00 from Caitlin Cronin at Canaccord Genuity, which represents a 70.5% increase from the current price of $44.00.
What is the lowest forecasted price for ENOV Enovis Corporation?
The lowest price target for ENOV is $50.00 from Robbie Marcus at JP Morgan, which represents a 13.6% increase from the current price of $44.00.
What is the overall ENOV consensus from analysts for Enovis Corporation?
The overall analyst consensus for ENOV is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $63.50.
How accurate are ENOV stock price projections?
Stock price projections, including those for Enovis Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.